Publication | Open Access

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Hematological MalignancyLymphoid NeoplasiaOncologyMalignant Blood DisorderClinical TrialsImmune Checkpoint InhibitorInterim ResultsPlacebo-controlled TrialPharmacotherapyImmunotherapyMedicineRadiation OncologyPhase 3Health Sciences